SARS-CoV-2 Period Seroprevalence and Related Factors, Hillsborough County, Florida, USA, October 2020–March 2021

Giuliano, Anna R.; Pilon-Thomas, Shari; Schell, Michael J.; Abrahamsen, Martha; Islam, Jessica Y.; Isaacs-Soriano, Kimberly; Kennedy, Kayoko; Dukes, Christopher W.; Whiting, Junmin; Rathwell, Julie; Hensel, Jonathan A.; Mangual, Leslie N.; Schonbrunn, Ernst; Bikowitz, Melissa; Grassie, Dylan; Yang, Yan

doi:10.3201/eid2803.211495

i

SARS-CoV-2 Period Seroprevalence and Related Factors, Hillsborough County, Florida, USA, October 2020–March 2021

Supporting Files

3 2022
By Giuliano, Anna R. ; Pilon-Thomas, Shari ; Schell, Michael J. ; ...

File Language:

English

Details

Alternative Title:

Emerg Infect Dis
Personal Author:

Giuliano, Anna R. ; Pilon-Thomas, Shari ; Schell, Michael J. ; Abrahamsen, Martha ; Islam, Jessica Y. ; Isaacs-Soriano, Kimberly ; Kennedy, Kayoko ; Dukes, Christopher W. ; Whiting, Junmin ; Rathwell, Julie ; Hensel, Jonathan A. ; Mangual, Leslie N. ; Schonbrunn, Ernst ; Bikowitz, Melissa ; Grassie, Dylan ; Yang, Yan
Description:

Estimating the actual extent of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is challenging because virus test positivity data undercount the actual number and proportion of persons infected. SARS-CoV-2 seroprevalence is a marker of past SARS-CoV-2 infection regardless of presence or severity of symptoms and therefore is a robust biomarker of infection period prevalence. We estimated SARS-CoV-2 seroprevalence among residents of Hillsborough County, Florida, USA, to determine factors independently associated with SARS-CoV-2 antibody status overall and among asymptomatic antibody-positive persons. Among 867 participants, SARS-CoV-2 period prevalence (October 2020-March 2021) was 19.5% (asymptomatic seroprevalence was 8%). Seroprevalence was 2-fold higher than reported SARS-CoV-2 virus test positivity. Factors related to social distancing (e.g., essential worker status, not practicing social distancing, contact with a virus-positive person, and length of contact exposure time) were consistently associated with seroprevalence but did not differ by time since suspected or known infection (<6 months vs. >6 months).
Subjects:

Antibodies, Viral Covid-19 Humans Pandemics Sars-Cov-2 Seroepidemiologic Studies
Source:

Emerg Infect Dis. 2022; 28(3):556-563
Pubmed ID:

35081021
Pubmed Central ID:

PMC8888241
Document Type:

Journal Article
Funding:

HHSN272201400008C/AI/NIAID NIH HHSUnited States/ ; P30 CA076292/CA/NCI NIH HHSUnited States/
Place as Subject:

Florida
Volume:

28
Issue:

3
Collection(s):

Emerging Infectious Diseases
Main Document Checksum:

urn:sha256:7fafe96917060f0e82f883029fddea6581490bbb87c16df7a01654ce74ffb6dc
Download URL:

https://stacks.cdc.gov/view/cdc/115209/cdc_115209_DS1.pdf
File Type:

[PDF - 915.36 KB ]

File Language:

English

ON THIS PAGE

Details Supporting Files

CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.

As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.